Johnson & Johnson (NYSE: JNJ) reported fourth-quarter 2020 financial results before the regular market hours on Tuesday. The pharmaceutical giant reported fourth-quarter revenue of $22.5 billion, up 8% year-over-year, and higher than the Wall Street projection. Net income of $1.86 per share also topped the target that analysts had anticipated.
JNJ shares rose 1.8% immediately following the announcement. The stock has gained 11% in the trailing 12 months.
“We continue to progress our COVID-19 vaccine candidate and look forward to sharing details from our Phase 3 study soon. Johnson & Johnson was built for times like these, and I am extremely confident in our ability to deliver lasting value and continued innovation in 2021 and for years to come,” CEO Alex Gorsky said in a statement.
Prior performance
4Q19
Most Popular
IPO Alert: Here’s what to look for when CaliberCos goes public
The massive slowdown in the IPO market continued in the second half as the challenges posed by high inflation and interest rate hikes weighed on investor confidence. Meanwhile, there is
CarMax (KMX) Stock: Does the current dip offer a buying opportunity?
The automotive sector is one of the worst affected by the combination of high inflation and rising interest rates. Consumers have become more cautious and are prioritizing their purchases with
Ultimax Digital gears up for $10mln IPO. Here’s all you need to know
The IPO market has witnessed muted activity this year, and things don’t seem to have improved in the second half. The upcoming public listing of video game technology firm Ultimax
